ChargePoint Technology launches single-use technology as part of powder transfer solutions portfolio
Company's hybrid solution claims superior performance compared with tradition single-use technologies.
Contained and sterile transfer solutions expert, ChargePoint Technology has announced new, single-use additions to its portfolio - the ChargePoint Single Use Passive (SUP) and ChargeBag PE-S with new HiPure ULP7 PE film.
Together, the two products form a high performance, single-use package for the contained and sterile transfer of pharmaceutical powders between manufacturing process steps or even facilities.
The ChargePoint SUP is a disposable version of the passive mating half of the ChargePoint SBV (Split Butterfly Valve) technology, which forms a complete hybrid system to ensure users can take advantage of the benefits of disposable technology without compromising performance. This also ensures the new single-use products are compatible with existing ChargePoint SBV systems in the field.
Constructed completely of FDA and USP Class VI compliant materials, the SUP is both lightweight and cost effective, delivering containment and sterility assurance performance while eliminating the time and cost associated with cleaning, maintenance and validation.
The new ChargeBag PE-S is a flexible, single-use product container for the handling, storage and transfer of bio-pharmaceutical powders.
Manufactured from HiPure ULP7, a new proprietary film, developed exclusively by ChargePoint Technology, and compliance tested to meet the demands of even the most critical aseptic processing environments, the solution enables extremely high levels of integrity with optimised purity and robustness characteristics.
Chris Eccles, CEO, ChargePoint Technology says: “As pharmaceutical manufacturing environments evolve, we will continue to push the boundaries of innovation and remain at the forefront of contained transfer advancements, responding to the challenges of today and tomorrow. We are excited to take our first steps into the realm of single-use technology as we look for new ways to deliver compliant, flexible solutions to our customers.”
He continues: “Although traditional single-use technologies claim to deliver the same level of performance as some of the more robust solutions, the reality is this is not the case over repeated operations. ChargePoint’s hybrid solution delivers repeatable performance as well as offering several advantages to pharmaceutical manufacturers. The convenience and control benefits associated with pre-validated, ready to use solutions, that are easily integrated and perform to the highest level of containment and sterility assurance, are invaluable for our customers”.
In line with the next generation of transfer solutions, ChargePoint Technology is also introducing its latest update of the ChargePoint SBV system, Series 3. Featuring a new and improved locking mechanism with intuitive mechanical interlocks the system is operator friendly and reduces risk of part wear. On automatic versions, quick release actuators and sensor sockets ensure fast set up and changeover while improved access to the main disc seal makes maintenance steps more convenient than ever before.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance